The Lancet Diabetes and Endocrinology

ISSNs: 2213-8587

Additional searchable ISSN (electronic): 2213-8595

Elsevier, Oxford [u.a.]

Scopus rating (2023): CiteScore 61.5 SJR 10.247 SNIP 9.029

Journal

Titles	The Lancet Diabetes and Endocrinology The Lancet. Diabetes & endocrinology
Additional searchable titles	The lancet. Diabetes & endocrinology, Lancet Diabetes Endocrinol
ISSNs	2213-8587
Additional searchable ISSN (electronic)	2213-8595
Publisher	Elsevier, Oxford [u.a.]
ZDB-ID	2710046-7

Keywords

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Library keywords

610 Medicine and health

Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study

Karges, B., Rosenbauer, J., Stahl-Pehe, A., Flury, M., Biester, T., Tauschmann, M. & Lilienthal, E. & 3 others, Hamann, J., Galler, A. & Holl, R. W., Feb 2025, In: The Lancet. Diabetes & endocrinology. 13, 2, p. 88-96 9 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care

Bonifacio, E., Winkler, C., Achenbach, P. & Ziegler, A. G., Jun 2024, In: The Lancet Diabetes and Endocrinology. 12, 6, p. 376-378 3 p.

Research output: Contribution to journal › Letter › Contributed › peer-review

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

The EMPA-KIDNEY Collaborative Group & Paliege, A., Jan 2024, In: The Lancet. Diabetes & endocrinology. 12, 1, p. 39-50 12 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

The EMPA-KIDNEY Collaborative Group & Paliege, A., Jan 2024, In: The Lancet. Diabetes & endocrinology. 12, 1, p. 51-60 10 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)

Sandforth, A., von Schwartzenberg, R. J., Arreola, E. V., Hanson, R. L., Sancar, G., Katzenstein, S. & Lange, K. & 35 others, Preißl, H., Dreher, S. I., Weigert, C., Wagner, R., Kantartzis, K., Machann, J., Schick, F., Lehmann, R., Peter, A., Katsouli, N., Ntziachristos, V., Dannecker, C., Fritsche, L., Perakakis, N., Heni, M., Kopf, S., Pfeiffer, A. F. H., Kabisch, S., Stumvoll, M., Schwarz, P. E. H., Hauner, H., Lechner, A., Seissler, J., Yurchenko, I., Icks, A., Solimena, M., Häring, H. U., Szendroedi, J., Schürmann, A., de Angelis, M. H., Blüher, M., Roden, M., Bornstein, S. R., Stefan, N. & Fritsche, A., Nov 2023, In: The Lancet Diabetes and Endocrinology. 11, 11, p. 798-810 13 p.

Research output: Contribution to journal › Research article › Contributed › peer-review

View all research output (17)

Research Portal of the TU Dresden

The Lancet Diabetes and Endocrinology

Keywords

ASJC Scopus subject areas

Library keywords

Related content

Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study

Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)